ARDX — Ardelyx, Inc.

Summary of Ardelyx Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Product Revenues: $93.4 million, up 38% year-over-year from $67.8 million.
• IBSRELA Revenue: $70.1 million, a 58% increase compared to Q1 2025.
• XPHOZAH Revenue: $23.3 million, consistent with the prior year, but adjusted for a $3.8 million favorable return reserve in Q1 2025, indicating a 19% growth in paid prescriptions.
• Net Loss: $37.6 million, or $0.15 per share, an improvement from a loss of $41.1 million or $0.17 per share in Q1 2025.
• R&D Expenses: $20.2 million, up from $14.9 million in the same quarter last year, primarily due to the ACCEL Phase III trial.
• SG&A Expenses: $102.3 million, compared to $83.2 million in Q1 2025, reflecting ongoing investments in commercialization.
• Cash Position: $238.1 million in cash, cash equivalents, and short-term investments.

2. Strategic Updates and Business Highlights

• IBSRELA: Continued strong demand with a disciplined commercial strategy, positioning it as a first-line therapy for IBS-C patients. The company aims for IBSRELA to reach at least $1 billion in annual revenue by 2029.
• XPHOZAH: Growth driven by a patient-first strategy, with a 32% increase in total dispenses and a 19% rise in paid prescriptions.
• Pipeline Development: Initiated the ACCEL trial for IBSRELA in chronic idiopathic constipation (CIC) with rapid site activation and recruitment.
• Pediatric Program: Ongoing studies to evaluate IBSRELA in pediatric patients, which could extend the patent life of tenapanor by an additional six months.
• Executive Team Expansion: New appointments in key roles to strengthen the leadership team.

3. Forward Guidance and Outlook

• IBSRELA Revenue Guidance: Reiterated for 2026 at $410 million to $430 million, projecting 50% to 57% year-over-year growth.
• XPHOZAH Revenue Guidance: Also reiterated at $110 million to $120 million for 2026.
• Long-Term Projections: IBSRELA expected to achieve $1 billion in revenue by 2029, with a compound annual growth rate (CAGR) of 38%.

4. Bad News, Challenges, or Points of Concern

• Seasonality and Weather Impact: First-quarter performance was affected by seasonal dynamics and severe winter storms, although demand growth was still observed.
• R&D and SG&A Expenses: Increasing operational expenses due to investments in R&D and commercialization could pressure profitability in the short term.
• Market Competition: Potential competition from other therapies, such as Lilly's GIPR agonist for IBS-C, may impact future market share, though management remains confident in IBSRELA's positioning.

5. Notable Q&A Insights

• Demand Trends: Management expressed confidence in continued quarter-over-quarter growth for IBSRELA, despite Q1 challenges.
• Specialty Pharmacy Network: The IBSRELA Pharmacy Network is proving effective in improving prescription fulfillment and refill rates.
• CIC Enrollment: The pace of enrollment in the ACCEL trial is on track, with expectations for quality patient recruitment.
• Market Dynamics: The company is cautious about overestimating the CIC market size, noting that many patients are treated with over-the-counter medications.
• Leverage and Capital Allocation: Management indicated a willingness to leverage the balance sheet for growth opportunities but emphasized current financial strength and cash flow positivity potential.

Overall, Ardelyx demonstrated strong revenue growth in Q1 2026, with a focus on expanding its product offerings and pipeline while navigating challenges and competitive pressures.